- Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial2018 | 2. lékařská fakulta
- Central data monitoring in the multicentre randomised SafeBoosC-III trial - a pragmatic approach2021 | Publikace bez příslušnosti k fakultě
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival2010 | Lékařská fakulta v Hradci Králové
- A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis2014 | 1. lékařská fakulta
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL2009 | 3. lékařská fakulta
- The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial2019 | Lékařská fakulta v Plzni
- Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III Trial2022 | Publikace bez příslušnosti k fakultě
- EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer2008 | 2. lékařská fakulta
- Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma2017 | 1. lékařská fakulta
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma a randomised, double-blind phase III trial2007 | Lékařská fakulta v Hradci Králové
- Phase III Trial Comparing Vinflunine With Docetaxel in Second-Line Advanced Non-Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy2010 | 3. lékařská fakulta
- Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial2018 | Lékařská fakulta v Hradci Králové
- Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial2023 | 1. lékařská fakulta
- Bevacizumab plus interferon alf 2a při léčbě metastáz ledvin2007 | 1. lékařská fakulta
- Cerebral near-infrared spectroscopy monitoring versus treatment as usual for extremely preterm infants: A protocol for the SafeBoosC randomised clinical phase III trial2019 | Publikace bez příslušnosti k fakultě
- Detailed statistical analysis plan for the SafeBoosC III trial: A multinational randomised clinical trial assessing treatment guided by cerebral oxygenation monitoring versus treatment as usual in extremely preterm infants2019 | Publikace bez příslušnosti k fakultě
- Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)2019 | 3. lékařská fakulta
- Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma2023 | Ústřední knihovna
- Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial2020 | 1. lékařská fakulta
- Multicentrická , randomizovaná , otevřená studie fáze III decitabin versus léčba na přání pacienta s poradenstvím lékaře, buď s podpůrnou péčí nebo nízkou dávkou cytarabinu u léčby starších pacientů s nově diagnostikovanou akutní myeloidní leukémií2012 | 1. lékařská fakulta
- AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial2023 | 1. lékařská fakulta
- Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)2010 | 3. lékařská fakulta
- Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials2021 | Farmaceutická fakulta v Hradci Králové
- Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO-The MIMOSA Study2013 | 1. lékařsk á fakulta
- Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma2019 | Lékařská fakulta v Hradci Králové
- A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)2022 | 3. lékařská fakulta
- Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial2023 | Lékařská fakulta v Hradci Králové
- Eribulin mesylát (Halaven (R)) - nová naděje pro předléčené pacientky s pokročilým a metastatickým karcinomem prsu2015 | 1. lékařská fakulta
- A Randomized Phase III Trial Comparing Irinotecan (IRI) + 5FU/Folinic Acid (FA) to the Same Schedule of 5FU/FA in Patients (pts) with Metastatic Colorectal Cancer (MCRC) as Front Line Chemotherapy (CT)1999 | Publikace bez příslušnosti k fakultě
- A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer2008 | 3. lékařská fakulta